Trial · NCT05604209
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) | C62-M4 | 12.5 | 95% Confidence Interval 0.32 to 52.7 | percentage of participants | |
| Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) | C1C62-M3M4 | 0 | 95% Confidence Interval 0 to 36.9 | percentage of participants | |
| Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) | Placebo | 0 | 95% Confidence Interval 0 to 84.2 | percentage of participants | |
| Percent of Participants With a Grade 1 or Higher Treatment-Related Adverse Event (AE) | C62-M4 | 87.5 | 95% Confidence Interval 47.4 to 99.7 | percentage of participants | |
| Percent of Participants With a Grade 1 or Higher Treatment-Related Adverse Event (AE) | C1C62-M3M4 | 100 | 95% Confidence Interval 63.1 to 100 | percentage of participants | |
| Percent of Participants With a Grade 1 or Higher Treatment-Related Adverse Event (AE) | Placebo | 50 | 95% Confidence Interval 1.3 to 98.7 | percentage of participants | |
| Median Fold-change in Magnitude of T-cell Response to HIV-1 Mosaic-1 Immunogen | C62-M4 | 1.15 | Inter-Quartile Range 0.32 to 1.92 | log2 fold change | |
| Median Fold-change in Magnitude of T-cell Response to HIV-1 Mosaic-1 Immunogen | C1C62-M3M4 | 1.66 | Inter-Quartile Range 1.29 to 2.26 | log2 fold change | |
| Median Fold-change in Magnitude of T-cell Response to HIV-1 Mosaic-2 Immunogen | C62-M4 | 1.79 | Inter-Quartile Range 1.06 to 1.92 | log2 fold change | |
| Median Fold-change in Magnitude of T-cell Response to HIV-1 Mosaic-2 Immunogen | C1C62-M3M4 | 1.66 | Inter-Quartile Range 1.16 to 2.26 | log2 fold change | |
| Median Fold-change in Magnitude of T-cell Response to HIV-1 Mosaic-1 Immunogen | C62-M4 | 1.09 | Inter-Quartile Range 0.50 to 1.89 | log2 fold change | |
| Median Fold-change in Magnitude of T-cell Response to HIV-1 Mosaic-1 Immunogen | C1C62-M3M4 | 2.00 | Inter-Quartile Range 1.03 to 3.47 | log2 fold change | |
| Median Fold-change in Magnitude of T-cell Response to HIV-1 Mosaic-2 Immunogen | C62-M4 | 1.57 | Inter-Quartile Range 1.06 to 1.89 | log2 fold change | |
| Median Fold-change in Magnitude of T-cell Response to HIV-1 Mosaic-2 Immunogen | C1C62-M3M4 | 1.78 | Inter-Quartile Range 0.96 to 3.47 | log2 fold change | |
| Median Change in Breadth of T-cell Responses Targeting Conserved HIV-1 Immunogen Subpools | C62-M4 | 1.0 | Inter-Quartile Range 0.5 to 1.5 | subpools | |
| Median Change in Breadth of T-cell Responses Targeting Conserved HIV-1 Immunogen Subpools | C1C62-M3M4 | 2.0 | Inter-Quartile Range 1.25 to 2.5 | subpools |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05604209/results